Zacks.com on MSN
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 ...
Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...
Since being approved, Wegovy's popularity has soared, to the point where the drug has made its maker, Novo Nordisk -- for ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more ...
Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...
Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...
Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...
Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...
Eli Lilly is currently redefining its market position through a series of strategic developments. The pharmaceutical giant ...
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results